1
Active FU- based adjuvant treatment was significant only for OS in this multivariate model.
2
Based on recent evidence, platinum- based adjuvant chemotherapy after complete resection should be considered.
3
In subset analysis, the signature identified patients likely to benefit from taxane- based adjuvant chemotherapy.
4
Patients without BRCA1 expression can benefit from platinum- based adjuvant chemotherapy.
5
The benefit of 5-fluorouracil- based adjuvant chemotherapy was evaluated based on poorly differentiated cluster grade.
6
Thirty-seven patients also received three cycles of cisplatin- based adjuvant chemotherapy.
7
The impact of 5FU- based adjuvant therapy on the rate of distant recurrence has been modest.
8
The aim of our study was to evaluate survival advantage of CDDP- based adjuvant therapy compared with short-term immunochemotherapy.
9
Oxaliplatin- based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade.
10
The relationships between BRCA1 expression and existing prognostic factors, platinum- based adjuvant chemotherapy, disease-free survival, and overall survival were analyzed.
11
The evidence supports routine platinum- based adjuvant chemotherapy following complete resection of stage IIIA lung cancer encountered unexpectedly at surgery.
12
It provides an alternative regimen for patients who have previously received anthracycline- based adjuvant chemotherapy or in whom anthracyclines cannot be used.
13
We aimed to investigate the association between poorly differentiated cluster and the efficacy of 5-fluorouracil- based adjuvant chemotherapy in stage III colorectal cancer.
14
This study demonstrates a benefit in terms of OS and DFS for patients with stage IV-NED breast cancer who receive doxorubicin- based adjuvant chemotherapy.
15
The aim of this study is to identify the prognostic significance of BRCA1 in patients with gastric cancer undergoing surgery and platinum- based adjuvant chemotherapy.
16
The increase in SI may be a marker of oxaliplatin-induced hepatic injury and should be investigated further in prospective longitudinal studies of oxaliplatin- based adjuvant chemotherapy.